Edgestream Partners L.P. acquired a new stake in Danaher Corporation (NYSE:DHR – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 5,137 shares of the conglomerate’s stock, valued at approximately $1,138,000.
Several other large investors have also recently made changes to their positions in DHR. BlackRock Inc. purchased a new stake in Danaher during the second quarter worth about $10,492,520,000. Wellington Management Group LLP raised its position in Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares during the period. Jupiter Topco LLC purchased a new position in Danaher in the second quarter valued at about $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher in the second quarter valued at about $1,287,949,000. Finally, Fisher Asset Management LLC boosted its stake in Danaher by 2.0% in the third quarter. Fisher Asset Management LLC now owns 4,573,887 shares of the conglomerate’s stock valued at $1,013,345,000 after acquiring an additional 89,113 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Danaher
In other news, CAO Christopher Bouda sold 7,598 shares of the company’s stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total value of $1,782,186.88. Following the transaction, the chief accounting officer owned 9,107 shares of the company’s stock, valued at approximately $2,136,137.92. This represents a 45.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gregory M. Milosevich sold 2,100 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at $5,158,277.54. This trade represents a 8.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 10.80% of the company’s stock.
Danaher Stock Down 3.1%
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. The firm had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.89 earnings per share. On average, equities analysts predict that Danaher Corporation will post 8.59 EPS for the current fiscal year.
Danaher Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were paid a $0.40 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is currently 26.19%.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on DHR. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Robert W. Baird upped their price objective on Danaher from $246.00 to $254.00 and gave the company an “outperform” rating in a research note on Thursday, October 22nd. Barclays upped their price objective on Danaher from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. UBS Group reissued a “buy” rating and issued a $260.00 target price on shares of Danaher in a research report on Thursday, October 22nd. Finally, DZ Bank lowered Danaher from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $242.91.
Get Our Latest Stock Analysis on Danaher
About Danaher
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
Featured Articles
- Five stocks we like better than Danaher
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
